FORM
6-K
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
For
the Month of August , 2024
Commission
File Number 0-51504
GENETIC
TECHNOLOGIES LIMITED
(Exact
Name as Specified in its Charter)
N/A
(Translation
of Registrant’s Name)
60-66
Hanover Street
Fitzroy
Victoria
3065 Australia
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant’s Registration Statement
on Form F-3 (File Nos. 333-276168), to be a part thereof
from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
August 15, 2024
GENETIC
TECHNOLOGIES LIMITED |
|
|
|
By: |
/s/
Mark Ziirsen |
|
Name: |
Mark
Ziirsen |
|
Title: |
Company
Secretary |
|
Exhibit
99.1
ASX
Market Announcement |
![](https://www.sec.gov/Archives/edgar/data/1166272/000149315224032505/ex99-1_001.jpg) |
Global
launch of geneType™ on wholly owned EasyDNA platform
Melbourne
Australia, August 15, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global
leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce
the global launch of the geneType™ Risk Assessment portfolio on our wholly owned EasyDNA platform currently selling in 42 countries.
The
company is positioned to launch the geneType™ personalized risk tests on the EasyDNA platform with the potential to reach 42 countries
and significantly expand on the current A$7.5m annual revenues.
This
expansion allows the company to promote and sell our most powerful geneType™ innovation on our most profitable channel to realise
more than 70% gross margin. This key step change in conjunction with the company structural reset will reduce our cash burn to under
A$200k per month from the previous A$800k driving the company towards its profitability target.
The
availability of geneType™ on EasyDNA’s consumer platform will accelerate global access. In the US, building on the successful
Influencer campaigns and Stayhealthy® initiatives, the Company believes this is the right time to add geneType™ to the EasyDNA
marketplace. The company has built a streamlined online process for both clinicians and consumers with our partners, Nest Genomics, DNA
Nexus, DNA Visit, Gene By Gene and Fabric Genomics.
Aligned
in our mission to transform the approach to population healthcare on a personalised basis, these partnerships support a telehealth-enabled
access to clinical testing. The placement of the geneType™ consumer-initiated pipeline on the EasyDNA platform will increase the
visibility and reach of the product line, while maintaining the required clinical oversight.
This
pipeline enables a uniform operational workflow regardless of specimen origin. All laboratory processing of samples will be carried out
through GTG’s laboratory partner Gene By Gene. Data analysis, a critical element of GTG’s intellectual property and accreditation
status, will remain in our Australian-based laboratory utilizing the Company’s cloud-based algorithms allowing GTG to process data
in local environments according to local data regulations by country.
The
new initiative launched in July is designed to streamline completion of the clinical questionnaire and the communication of results.
GTG has implemented a “user-friendly” consumer interface with Nest Genomics. Nest Genomics are experts in the field of genetic-based,
patient-facing communication enabling GTG to harness their ability to support the post-test continuum of care. GTG has not only built
a test that empowers consumers to understand their risk of serious disease but has built a pipeline that enables consumers to act on
that disease risk by facilitating communication with their healthcare providers. This pipeline will now be made available on the EasyDNA
platform for increased consumer and practitioner access.
The
UK market has demonstrated a proven appetite and strong interest in genetic testing. GTG believes this initiative will resonate well
in this market given much of the data that drove the initial development of geneType™ is based on the unique UK biobank. In Australia,
as in the US, tests will be available via the EasyDNA platform and local medical providers using telehealth appointments and in-person
engagement with consumers.
The
combination of genetics and clinical risk covers both nature and nurture and provides a truly comprehensive view of an individual’s
personal risk of serious disease. Our geneType patent portfolio with over $50m invested to date creates a moat in these areas as the
market is expected to grow exponentially in the near term.
The
EasyDNA business founded some 17 years ago is a leading name in the consumer health and wellness markets. Its product range includes
paternity testing, animal health, general consumer health and wellness across over 42 countries with the initial focus on English language
markets.
-
END –
Authorised
for release by the Board of Directors.
For
inquiries, contact:
Peter
Rubinstein
E:
investors@genetype.com
About
Genetic Technologies Limited
Genetic
Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests
in health, wellness and serious disease through its geneType™ and EasyDNA brands. GTG offers cancer predictive testing and assessment
tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform
that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and
individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues
to develop risk assessment products. For more information, please visit www.genetype.com
About
EasyDNA
EasyDNA
is an online provider of genetic testing services established in 2007 and developed into an online network of over 70 websites in over
42 countries. EasyDNA’s network of online retail sales platforms offers fast and affordable home DNA testing that is reliable and
confidential. They also offer a number of lifestyle and health and wellbeing tests, and animal testing relating to allergies and tolerances.
EasyDNA is a pioneering provider of genetic testing services, dedicated to delivering accurate and confidential results to individuals
and organizations worldwide.
Forward
Looking Statements
This
announcement may contain forward-looking statements about the Company’s expectations, beliefs or intentions regarding, among other
things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made
or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking
words such as “believe,” “expect,” “intend,” “plan,” “may,” “should”
or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not
limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made
by or with the approval of one of the Company’s authorized executive officers. Forward-looking statements relate to anticipated
or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company’s actual
results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause
the Company’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking
statements as detailed in the Company’s filings with the Securities and Exchange Commission and in its periodic filings with the
ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities
values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any
obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except
as required by law.
Genetic Technologies (PK) (USOTC:GNTLF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genetic Technologies (PK) (USOTC:GNTLF)
Historical Stock Chart
From Sep 2023 to Sep 2024